HBV, HCV, and HIV Screening Results of Deceased Solid Organ Donors
Increased risk donors may be significantly more likely to be HCV- and HBV-positive compared with standard risk donors.
Transplantation
Prognostic Index for Post-Engraftment Invasive Fungal Disease Validated
First of its kind prognostic index predicts the occurrence of post-engraftment invasive fungal disease after allogeneic hematopoietic stem cell transplant.
Fecal Microbiota Transplantation and Vancomycin for Recurrent C difficile
The combination of vancomycin and fecal microbiota transplantation was found to be superior to fidaxomicin or vancomycin for patients with recurrent CDI.
Vaccine-Preventable Infections Common After Solid Organ Transplants in Children
Hospitalization for vaccine-preventable infections occurs in more than 15 percent of pediatric solid organ transplant recipients in the first five years after surgery.
Many Patients Are Unwilling to Accept Transplantation of an HCV-Positive Organ
The availability of organs that are positive for HCV can potentially decrease the length of time on organ transplantation waitlists.
Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients
The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.
Oral Vancomycin May Prevent Clostridioides Difficile Infection in Transplant Recipients
Oral vancomycin is effective in preventing C difficile infection in allogeneic hematopoietic cell transplant patients and does not raise the risk for GVHD.
Renal-Replacement Timing Has No Effect in Kidney Injury, Sepsis
For patients with early-stage septic shock and severe acute kidney injury, 90-day mortality does not differ for patients randomly assigned to an early strategy for initiation of renal-replacement therapy versus a delayed strategy.
C difficile Tied to Increased Graft Loss in Solid Organ Recipients
For solid organ transplant recipients, Clostridium difficile infection is associated with increased graft loss.
Mavyret Labeling Updated With Dosing for Liver, Kidney Transplant Patients
The Dosage and Administration section has been revised to state that Mavyret is recommended for 12 weeks in liver or kidney transplant recipients.
Next post in Prevention
